Search Results - "MARTELL, R. E"

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors by Soria, J.-C., Cortes, J., Massard, C., Armand, J.-P., De Andreis, D., Ropert, S., Lopez, E., Catteau, A., James, J., Marier, J.-F., Beliveau, M., Martell, R.E., Baselga, J.

“…We studied the safety, tolerability, and recommended dose of BMS-599626, an orally bioavailable inhibitor of the human epidermal growth factor receptor (HER)…”
Get full text

Impact of Therapy With Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections in Patients With Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011 by MORRISON, Vicki A, RAI, Kanti R, SCHIFFER, Charles A, PETERSON, Bercedis L, KOLITZ, Jonathan E, ELIAS, Laurence, APPELBAUM, Frederick R, HINES, John D, SHEPHERD, Lois, MARTELL, Robert E, LARSON, Richard A

“…We sought to determine whether therapy with single-agent fludarabine compared with chlorambucil alone or the combination of both agents had an impact on the…”
Get full text

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors by Soria, J-C, Cortes, J, Massard, C, Armand, J-P, De Andreis, D, Ropert, S, Lopez, E, Catteau, A, James, J, Marier, J-F, Beliveau, M, Martell, R E, Baselga, J

Get full text

1,25-Dihydroxyvitamin D3 regulation of phorbol ester receptors in HL-60 leukemia cells by Martell, R.E., Simpson, R.U., Taylor, J.M.

“…In this study the relationship between cell binding of phorbol 12,13-dibutyrate (PDBu) and induction of differentiation by 1,25-dihydroxyvitamin D3…”
Get full text

Identification of lamin B and histones as 1,25-dihydroxyvitamin D3-regulated nuclear phosphoproteins in HL-60 cells by MARTELL, R. E, STRAHLER, J. R, SIMPSON, R. U

“…1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3)-induced differentiation of HL-60 leukemia cells is accompanied by a number of cellular changes including regulation of…”
Get full text

OVX1 and CEA in patients with colon carcinoma, colon polyps and benign colon disorders by Martell, R E, Xu, F J, Davis, W Z, Anselmino, L, Yu, Y H, Daly, L, Bast, Jr, R C

“…The OVX1 tumor marker promises to complement CA125 for detection of early stage ovarian carcinoma. OVX1 has also been shown to be elevated in colon cancer…”
Get more information

Effects of protein kinase inhibitors 1(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7) and N-[2-guanidinoethyl]-5-isoquinolinesulfonamide hydrochloride (HA1004) on calcitriol-induced differentiation of HL-60 cells by Martell, R E, Simpson, R U, Hsu, T

“…HL-60 promyelocytic leukemia cells were induced to differentiate by 1,25-dihydroxyvitamin D3 (calcitriol) into mature monocytes. Differentiation was assessed…”
Get more information

Reconstitution of DNA Synthetic Capacity in Senescent Normal Human Fibroblasts by Expressing Cellular Factors E2F and Mdm2 by Sarraj, Sara, Farb, Roderick, Martell, Robert E.

“…Unraveling the mechanisms underlying cellular senescence will contribute to the understanding of processes involved in aging and cancer. We sought to determine…”
Get full text

Iodoaryl analogs of dioctanoylglycerol and 1-oleoyl-2-acetylglycerol as probes for protein kinase C by Strawn, Laurie M, Martell, Robert E, Simpson, Robert U, Leach, Karen L, Counsell, Raymond E

“…Analogues of dioctanoylglycerol (diC8) and 1-oleoyl-2-acetylglycerol (OAG) containing an iodoaryl group have been synthesized and shown to compete with…”
Get full text

Therapeutic enhancement of IL-2 through molecular design by Cassell, Delanie J, Choudhri, Shurjeel, Humphrey, Rachel, Martell, Robert E, Reynolds, Theresa, Shanafelt, Armen B

“…A recombinant human IL-2 analog (rIL-2, Proleukin) is currently being evaluated for clinical benefit in HIV infected patients. It is approved for therapy of…”
Get more information

Synthesis and evaluation of iodinated analogs of diacylglycerols as potential probes for protein kinase C by Strawn, Laurie M, Martell, Robert E, Simpson, Robert U, Leach, Karen L, Counsell, Raymond E

“…Analogues of diacylglycerol containing a 3-(3-amino-2,4,6-triiodophenyl)-2-ethylpropanoyl or 3-(3-amino-2,4,6-triiodophenyl)propanoyl group in the 2-position…”
Get full text

Phase I study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy is available by Martell, R. E., Chiorean, E. G., Youssoufian, H., Rutstein, M. D., Pytowski, B., Benjamin, L., Abad, L., Patel, J., Steele, T., Dowd, M., Qin, A., Kukel, C. F., Fox, F. E., Dontabhaktuni, A., Morozov, A.

“…Abstract only…”
Get full text

Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase I study (study 265-101) by Drouin, M. A., Kollmannsberger, C. K., Uronis, H. E., Martell, R. E., Wang, J., Dubay, M., Dupont, I., Besterman, J. M., Hurwitz, H., Shapiro, G.

“…Abstract only…”
Get full text

A phase I study of oral administration of MGCD265 in patients with advanced malignancies (study 265-102) by Heath, E. I., LoRusso, P., Kurzrock, R., Falchook, G. S., Maroun, C. R., Drouin, M. A., Juretic, M., Martell, R. E., Besterman, J. M., Wheler, J. J.

“…Abstract only…”
Get full text

Phase II study of MGCD0103 in patients with relapsed follicular lymphoma (FL): Study reinitiation and update of clinical efficacy and safety by Martell, R. E., Younes, A., Assouline, S. E., Rizzieri, D., Fox, S., Drouin, M. A., Wilhelm, J., Mehran, M., Besterman, J. M., Van Der Jagt, R. H.

“…Abstract only…”
Get full text

Patterns of human chorionic gonadotropin expression in untreated and 8-bromoadenosine-treated JAR choriocarcinoma cells by Martell, R E, Ruddon, R W

“…Although the biosynthesis and secretion of hCG by both normal and neoplastic trophoblasts have been documented, the regulation of these events is not well…”
Get more information

Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib by Adjei, A. A., Sosman, J. A., Martell, R. E., Dy, G. K., Goff, L. W., Ma, W. W., Horn, L., Fetterly, G. J., Michael, S. A., Means, J. A., Chai, F., Lamar, M., Strauss, G. M., Chiang, W., Jarboe, J., Schwartz, B. E., Puzanov, I.

“…Abstract only…”
Get full text

Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL) by Bociek, R. G., Kuruvilla, J., Pro, B., Wedgwood, A., Li, Z., Drouin, M., Patterson, T., Ward, R., Martell, R. E., Younes, A.

“…Abstract only…”
Get full text

Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study by Crump, M., Andreadis, C., Assouline, S., Rizzieri, D., Wedgwood, A., McLaughlin, P., Laille, E., Li, Z., Martell, R. E., Younes, A.

“…Abstract only…”
Get full text

A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma by Younes, A., Fanale, M., Pro, B., McLaughlin, P., Neelapu, S., Fayad, L., Wedgwood, A., Dubay, M., Backstrom, J., Martell, R. E.

“…Abstract only 8000 Background: MGCD0103 is a non-hydroxamate, isotype-selective, inhibitor of human HDACs. Abnormal regulation of HDAC activity is associated…”
Get full text